Biblioteca Digital Médico Científica 2.0

Entrar

Documento

Documento, Documento-Fibrosis Hepática

Global epidemiology of cirrhosis — aetiology, trends and predictions.

/

Cirrhosis is an important cause of morbidity and mortality in people with chronic liver disease worldwide. In 2019, cirrhosis was associated with 2.4% of global deaths. Owing to the rising prevalence of obesity and increased alcohol consumption on the one hand, and improvements in the management of hepatitis B virus and hepatitis C virus infections on the other, the epidemiology and burden of cirrhosis are changing…

Documento, Documento-Fibrosis Pulmonar

Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.

/

Progressive fibrosing interstitial lung disease (PF-ILD) describes a phenotypic subset of interstitial lung diseases characterized by progressive, intractable lung fibrosis. PF-ILD is separate from, but has radiographic, histopathologic, and clinical similarities to idiopathic pulmonary fibrosis. Two antifibrotic medications, nintedanib and pirfenidone, have been approved for use in patients with idiopathic pulmonary fibrosis…

Documento, Documento-Fibrosis Hepática

Epidemiology of liver cirrhosis and associated complications: Current knowledge and future directions.

/

Cirrhosis causes a heavy global burden. In this review, we summarized up-todate epidemiological features of cirrhosis and its complications. Recent epidemiological studies reported an increase in the prevalence of cirrhosis in 2017 compared to in 1990 in both men and women, with 5.2 million cases of cirrhosis and chronic liver disease occurring in 2017…

Scroll al inicio

Acceso para profesionales de la salud